Vaxeal has developed exceptional and innovative technology platforms for the development of advanced immunotherapies

Main issues in current vaccine approaches

A central aim of modern cancer therapies is the induction of effective an anti-tumour immunity in cancer patients leading to the elimination of tumors and long-lasting protection against relapses. In this regard, modern therapeutic vaccination has been shown to elicit tumor antigen specific T-cell immunity.

Nevertheless, cancer vaccines are showing modest clinical effects such as objective tumor responses in a small proportion of immunized patients and increase in overall survival for a few vaccines.

Many studies have identified the two main sets of hurdles in cancer vaccine development. The first arises from the sub-optimal composition and design of the tumor antigen-based vaccines leading to their weak immunogenicity and difficulty in generating robust memory responses and in achieving the right balance of CD4+ and CD8+ T-cell responses. The second set of hurdles is the tumor-induced immunosuppressive mechanisms such as:

he induction of regulatory T-cells (Treg) in the tumour micro-environment. The over-expression of multiple immune regulatory checkpoints operating intrinsically in antigen activated T-cells and extrinsically within the tumour micro-environment, and The tumor-mediated angiogenesis.

Vaxeal has developed exceptional and innovative technology platforms for:

  • A rapid identification of relevant T-cell epitopes to be incorporated into the vaccine candidates and a rapid prediction of their immunogenicity in human
  • The design, formulation and validation of vaccine candidates;
  • Pre-clinical proof of concept studies to evaluate the immunogenicity and therapeutic activity of the vaccine candidates in relevant animal models
  • The evaluation of synergistic combination of the formulated vaccines with immunomodulatory agents
  • The immunomonitoring of clinical trials.

Immunogenicity Prediction

  • Rapid identification of relevant T cell epitopes
  • Immunogenicity prediction of selected epitopes in human

Formulation / Delivery

  • Production and formulation of the vaccine candidates
  • LS Peptide synthesis
  • Lipidation technology
  • Adjuvants selection

Pre-Clinical Validation

  • Pre-clinical proof of concept studies
  • Advanced in vitro assays and animal models to monitor immune responses & therapeutic efficacy

Combination Therapies

  • Synergistic combinations with Immune Checkpoint Inhibitors (ICIs)

Immuno-monitoring of clinical trials

  • Monitoring of the immunogenicity and efficacy of our vaccine candidates

Synergies between Vaxeal and its partners will improve patient access to new advanced immunotherapies

vaxeal tab